Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Levamisole was used in a double blind trial in 24 patients with severe rheumatoid arthritis (RA). Each patient received either levamisole 150 mg daily, or placebo for a period of 6 months in addition to nonsteroidal antiinflammatory therapy. Ten patients, 8 of whom were taking levamisole, failed to complete the trial. Clinically 3 or 4 patients on levamisole who completed the study showed improvement whereas 5 were considered improved on placebo. The high incidence of side effects, (rashes, gastrointestinal upset, stomatitis and depression) in the levamisole treated group indicates that this drug, in the dose used, was too toxic for the management of severe RA. A much lower incidence of side effects is reported with recent recommendations using much lower daily or even weekly dosage.
 ...
PMID:Levamisole in rheumatoid arthritis -- a double-blind study. 699 5

41 patients (pilot study-I) and 50 patients (multicenter study II) were randomized to receive as systemic chemotherapy for 6 courses with 5 FU alone (A) [440 (I)-450 (II) mg/m2 IV bolus, 5/21 days] or folinic acid followed by 5 FU (B) (respectively 200 and 370 mg/m2 IV bolus, 5/21 days). In the multicenter trial, oral levamisole at the dose of 150 mg/day (3/14 days) was added to chemotherapy for one year. Ten patients in study I and 19 patients in study II also received a post-operative course of intra-portal chemotherapy. Toxicity was evaluated respectively on 232 (I) and 276 (II) courses. Clinical limiting toxicities were stomatitis and diarrhea. In protocol II, a significant enhancement of grades 3-4 granulocyte toxicity was seen (17.3% of courses in II vs only 3.4% in I; p < 0.001). This was especially recorded in the group treated with 5-FU alone (26% of courses in A vs 11% in B; p < 0.001). Levamisole was therefore stopped in 12 cases (10 cases in A; 2 cases in B).
 ...
PMID:Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report. 765 45